Optimization of allogeneic transplant conditioning: not the time for dogma. - Wikidata - wikimedia - TriplyDB

Optimization of allogeneic transplant conditioning: not the time for dogma.

Optimization of allogeneic transplant conditioning: not the time for dogma.

http://www.wikidata.org/entity/Q36556498

about

Optimal prevention of seizures induced by high-dose busulfan Hematopoietic stem cell transplantation for MDS.Pharmacokinetic and pharmacodynamic analysis of inosine monophosphate dehydrogenase activity in hematopoietic cell transplantation recipients treated with mycophenolate mofetil.Recipient pretransplant inosine monophosphate dehydrogenase activity in nonmyeloablative hematopoietic cell transplantation Population pharmacokinetic/dynamic model of lymphosuppression after fludarabine administration.Pharmacogenetics of intravenous and oral busulfan in hematopoietic cell transplant recipients.Who is fit for allogeneic transplantation?Association of fludarabine pharmacokinetic/dynamic biomarkers with donor chimerism in nonmyeloablative HCT recipients Current status of allogeneic hematopoietic cell transplantation for MDS.Allogeneic hematopoietic cell transplantation for MDS: for whom, when and how?Population pharmacokinetics and dose optimization of mycophenolic acid in HCT recipients receiving oral mycophenolate mofetil.Pharmacokinetics, Pharmacodynamics and Pharmacogenomics of Immunosuppressants in Allogeneic Haematopoietic Cell Transplantation: Part I Nonrelapse mortality and mycophenolic acid exposure in nonmyeloablative hematopoietic cell transplantation Intracellular disposition of fludarabine triphosphate in human natural killer cells.Variation in prescribing patterns and therapeutic drug monitoring of intravenous busulfan in pediatric hematopoietic cell transplant recipients A limited sampling schedule to estimate individual pharmacokinetic parameters of fludarabine in hematopoietic cell transplant patients.Busulfan in infant to adult hematopoietic cell transplant recipients: a population pharmacokinetic model for initial and Bayesian dose personalization.Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: current status.Allogeneic transplantation in the UK: an aggregation of marginal gains?Optimizing drug therapy in pediatric SCT: focus on pharmacokinetics.Levetiracetam for the prevention of busulfan-induced seizures in pediatric hematopoietic cell transplantation recipients.Development of a population pharmacokinetics-based sampling schedule to target daily intravenous busulfan for outpatient clinic administration.

P2860

Q28301571-C7C7F2E6-3EC2-4EC1-ACEA-6A196B41F12D Q33767314-330094CE-7135-4825-AB2D-BF86834BB689 Q33905541-5F510636-836F-47AE-B3F4-D258C44F9E75 Q34175259-B9309624-F5DF-4A0C-B9F5-CA2ADCDE0E74 Q34807259-0B6ED61C-83BE-4384-B379-FE6E600A2A5A Q35053340-8FD2F2A8-E8D1-48E4-A95C-B0368484C8F8 Q35660739-0E86F36D-658F-468C-B189-526708525975 Q35811940-192A7BBB-6B35-4C5E-9BB2-CF2899D9D503 Q36063049-FD30F038-4456-43CF-846F-F47BD43E1589 Q36431041-2F1D14B9-0D48-4AB7-BBCD-FA1CD6DAB572 Q36728151-B61079D8-A03D-41A0-B896-E27651995232 Q36777599-562A96DB-9DD8-4549-B028-4DAD3282F31E Q37038889-5FB9A222-2605-4D63-91CC-8504EDE59AC5 Q37111568-BFDFD065-D2F9-4DB4-8794-CD5634D895F6 Q37224427-1A61B53A-78F0-4B46-8A44-962B6A504F82 Q37390905-26BD2951-2891-46A6-90B8-63C5A9619265 Q37624344-1831FCCA-6BAD-4815-AEB5-D57A5146B423 Q37964938-F1165E13-F848-4222-BB22-F07988A26499 Q38124363-0419D433-EE77-463C-ABEF-2A045BD86120 Q38262916-298E7154-D288-4B69-BEB9-69BD9945FC5B Q39747715-7FC29A9B-819D-40DE-B45D-8A34DF5C67AF Q43194170-50A0FB4B-5727-4442-83AE-A28547BF19E6

P2860

Optimization of allogeneic transplant conditioning: not the time for dogma.

http://www.wikidata.org/entity/Q36556498

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Optimization of allogeneic transplant conditioning: not the time for dogma.

@ast

Optimization of allogeneic transplant conditioning: not the time for dogma.

@en

type

label

Optimization of allogeneic transplant conditioning: not the time for dogma.

@ast

Optimization of allogeneic transplant conditioning: not the time for dogma.

@en

prefLabel

Optimization of allogeneic transplant conditioning: not the time for dogma.

@ast

Optimization of allogeneic transplant conditioning: not the time for dogma.

@en

P1433

Q36556498-7F2DFA2E-9671-4BAE-A73E-D203E55F98BA

P1476

Q36556498-8117C4DE-4220-4A3B-B93A-FF59A1E8C44E

P2093

Q36556498-2953E2D5-4CF3-478D-AFAC-752EFB9856AF

Q36556498-4CB81F7F-7E44-4B5E-AE63-AD985016744D

Q36556498-DE6188E1-9774-4522-B2BE-484FC5928196

P2860

Q36556498-038B25F7-62A8-430E-BBA4-0AFB6862272D

Q36556498-083DC1B9-5FB1-4699-9426-5F64D794DDCB

Q36556498-09F788C8-4023-4B05-A191-01DE068D28CD

Q36556498-0F7FB53A-3419-4D43-BD66-8ACC86574510

Q36556498-1168138A-9A49-43DC-A1A8-987729BB4774

Q36556498-158FDDAE-BD3E-4EC7-92FC-EF0BBC921CE9

Q36556498-1A8957C2-4692-48C6-8A53-0531810DE100

Q36556498-2502A392-933F-473C-AD75-4C71DC2353D1

Q36556498-291749F0-AFE3-410F-A87E-6A202CA55FA9

Q36556498-2BA8D4F6-0B9A-4DA8-9959-03B329B0DFAD

P2888

Q36556498-BD3732C5-2B2A-4F6D-92B9-D3B23FFB943D

P304

Q36556498-98F2EDB0-9BEE-43D2-A1E7-A0D0DB9AA227

P31

Q36556498-FD8E38BC-FF38-46BB-B366-95749EB0AB23

P356

Q36556498-9F7680CE-92A7-4824-8EEE-96A39FED4518

P433

Q36556498-69403F2A-08ED-408E-82C1-98FBB06957AD

P478

Q36556498-0F12C11F-0385-4220-AFBB-0B48ED54F467

P50

Q36556498-B0FFAE99-1509-4EF1-B5FE-FD0A0EAE4722

P577

Q36556498-3DA34A8E-E7F3-4354-9FEA-FAEA3351CCBF

P5875

Q36556498-E171C8D9-7E05-4A4B-9315-3E2E0747A03B

P698

Q36556498-033E043D-212B-40E2-9205-F3AC854B6679

P356

P1433

P1476

Optimization of allogeneic transplant conditioning: not the time for dogma.

@en

P2093

B L Scott

http://www.w3.org/2001/XMLSchema#string

E H Warren

http://www.w3.org/2001/XMLSchema#string

M B Maris

http://www.w3.org/2001/XMLSchema#string

P2860

A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia.

Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor

Identification of a polymorphic gene, BCL2A1, encoding two novel hematopoietic lineage-specific minor histocompatibility antigens

A human minor histocompatibility antigen specific for B cell acute lymphoblastic leukemia.

Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation.

Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes.

Molecules and mechanisms of the graft-versus-leukaemia effect.

NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses.

Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia

Graft-versus-leukemia reactions in allogeneic chimeras.

P2888

P304

1701-1705

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.LEU.2404327

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

Hans Joachim Deeg

P577

2006-08-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6897458

http://www.w3.org/2001/XMLSchema#string

P698

16888618

http://www.w3.org/2001/XMLSchema#string